Prostate cancer (PCa) is the most commonly diagnosed malignancy in Europe and the 3rd leading cause of cancer related death among men [1]. The progression of this disease is known to be associated with various epigenetic mechanisms, one of them being gene expression alterations by microRNAs (miRNAs) [2]. They are small, non-coding RNAs which bind to their target mRNAs and decrease gene expression at the post-transcriptional level [3]. Understanding interactions between specific miRNAs and their target genes would help to find novel ways to treat PCa earlier.
In the present study, we focused on histone methylation regulating (HM) genes as potential miRNA targets. Nine HM genes were selected for the analysis based on our previous PCa studies [4; Maleckaite et al., unpublished data]. Based on the database search results, potential regulatory miRNAs of the HM genes were identified and the hypothesized regulatory network was created. After evaluating baseline miRNA and HM gene expression levels, two miRNAs – miR-27a and miR-29a – were selected for loss-of-function in vitro experiments in the PC-3 cell line.
Based on the formed miRNA-HM gene regulatory network, miR-27a had four potential targets (KDM1A, KDM3A, KDM4B, and KDM5B) and miR-29a – five targets (KDM5A, KDM5B, KDM5D, KMT1E, and KMT5A) with one overlapping gene. According to the preliminary data, inhibition of miR-27a resulted in increased expression of KDM4B and KDM5B as expected, while inhibition of miR-29a induced upregulation of all its targets except KDM5D. Surprisingly, inhibitors of both miRNAs caused downregulation of KDM3A indicating a more complex way of HM gene regulation mechanism.
In conclusion, our preliminary data revealed miR-27a and miR-29a as potential regulators of specific HM genes in PCa. Further experiments would follow to validate these findings, as well as to evaluate cellular effects of the inhibition of the two miRNAs. Satisfying results would lay the basis for the use of miR-27a and miR-29a inhibitors as prospective PCa therapeutics in the future.